Amid the genomic revolution reshaping AML treatment, Karilyn Larkin, MD, speaks to why every patient deserves a personalized road to cure.
Karilyn Larkin, MD
Advertisement
Articles by Karilyn Larkin, MD
Karilyn Larkin, MD, weighs in on how decitabine/cedazuridine/venetoclax could transform the AML treatment experience—and the new responsibilities it places on patients.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
ATTR-CM Incidence, Prevalence Rose Sharply in the US
2
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
3
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
4
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
5